Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study

Table 5 Comparison of utility values for stable and progressive health state

	Base case utilities	Scenario 1	Scenario 2	Scenario 3	Swinburn 2012 [6]	SMC 698/11 [8]
Stable disease	0.776	0.780	0.793	0.796	0.771	n/a
Progressive disease	0.726	0.732	0.764	0.764	0.612	0.73^a

Note:^a, 0.73 relates to pre-progression for patients with pancreatic neuroendocrine tumours with disease progression (and therefore corresponds to progressive disease in this analysis) and the utility value for these patients post-progression is 0.596

ISSN: 1477-7525